triple hormone receptor agonist retatrutide Dr. Rutman | Weight Loss | Aesthetics | Regenerative First Retatrutide phase 3 data,
Description
It is continuing the development of an oral GIPR antagonist candidate (PF-07976016) in Phase 2, and maintains an earlier-stage obesity pipeline
I eat a healthy mix
Of note, a recent study by Packer et al
17 Albert SG, Wood EM, Ahir V
